Taiwan Not To Have Adimmune Vaccine ‘Until November At Earliest'
This article was originally published in PharmAsia News
Adimmune, Taiwan's only producer of an H1N1 flu vaccine, says it does not expect to begin human trials on its drug until October. Tests are underway on animals for a two-dose variety of the vaccine. The minister of health said the vaccine would not be available to the public "until November at the earliest." The government already has ordered all of the 5 million doses Adimmune expects to produce, so it is looking abroad for other suppliers, particularly ones that might be able to deliver ahead of Adimmune. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.